{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(35)"],"submitter":["Tack GJ"],"pubmed_abstract":["Aim
To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN-PEP) to mitigate the immunogenic effects of gluten in celiac patients.Methods
Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included. In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase). After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase). Measurements at base"],"journal":["World journal of gastroenterology"],"pagination":["5837-47"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3793137"],"repository":["biostudies-literature"],"pubmed_title":["Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study."],"pmcid":["PMC3793137"],"pubmed_authors":["Edens L","Koning F","van Bergen J","Bruins MJ","Korponay-Szabo I","Schreurs MW","Kooy-Winkelaar EM","van de Water JM","Mulder CJ","Bonnet P","Vreugdenhil AC","Tack GJ","von Blomberg BM"],"additional_accession":[]},"is_claimable":false,"name":"Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study.","description":"Aim
To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN-PEP) to mitigate the immunogenic effects of gluten in celiac patients.Methods
Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included. In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase). After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase). Measurements at base","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Sep","modification":"2025-04-04T12:56:07.341Z","creation":"2019-03-27T01:17:00Z"},"accession":"S-EPMC3793137","cross_references":{"pubmed":["24124328"],"doi":["10.3748/wjg.v19.i35.5837"]}}